Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):961; doi:10.1093/jnci/93.13.961-b
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Arnold, K.
Right arrow Articles by Eckstein, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Arnold, K.
Right arrow Articles by Eckstein, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 961, July 4, 2001
© 2001 Oxford University Press

MEMORANDUM FOR: Science Writers and Editors on the Journal Press List

Genetic Modification of Cancer Cells Slows Blood Vessel Development

June 28, 2001 (EMBARGOED FOR RELEASE 4 P.M. EDT July 3)

Katherine Arnold, Deputy News Editor, Dan Eckstein, (301) 986-1891, ext. 112

New research shows that genetic manipulation of cancer cells may provide a means of slowing blood vessel development (angiogenesis) and inhibiting tumor growth.

Andrew Feldman, M.D., and Steven Libutti, M.D., working with their colleagues at the National Cancer Institute, Bethesda, Md., transferred the gene encoding the angiogenesis inhibitor endostatin into the mouse liver cell line NMuLi. Various tests proved that these modified cells produced endostatin in vivo . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?